The Goldman Sachs Group Lowers Abbott Laboratories (NYSE:ABT) Price Target to $121.00

Abbott Laboratories (NYSE:ABT) had its target price dropped by analysts at The Goldman Sachs Group from $140.00 to $121.00 in a report released on Wednesday, MarketBeat reports. The firm presently has a “buy” rating on the healthcare product maker’s stock. The Goldman Sachs Group’s price target would suggest a potential upside of 17.78% from the stock’s previous close.

Several other equities analysts also recently weighed in on ABT. Leerink Partners reduced their price target on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a report on Friday, January 30th. BTIG Research reduced their price target on Abbott Laboratories from $140.00 to $131.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Citigroup reduced their price target on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. Royal Bank Of Canada reduced their price target on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, Weiss Ratings downgraded Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $134.58.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $102.73 on Wednesday. Abbott Laboratories has a 1-year low of $100.88 and a 1-year high of $139.06. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The business has a fifty day moving average price of $109.10 and a 200-day moving average price of $120.23. The company has a market capitalization of $178.92 billion, a PE ratio of 27.62, a PEG ratio of 1.65 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same period last year, the company earned $1.34 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Insider Activity at Abbott Laboratories

In related news, EVP Mary K. Moreland sold 613 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the sale, the executive vice president directly owned 104,291 shares of the company’s stock, valued at $12,053,953.78. This trade represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Eric Shroff sold 709 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the sale, the senior vice president directly owned 39,164 shares in the company, valued at $4,526,575.12. This trade represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,055 shares of company stock valued at $353,097 over the last three months. 0.46% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Cornerstone Financial Management LLC purchased a new position in Abbott Laboratories in the fourth quarter worth about $25,000. MidAtlantic Capital Management Inc. purchased a new position in Abbott Laboratories in the fourth quarter worth about $25,000. Purpose Unlimited Inc. purchased a new position in Abbott Laboratories in the fourth quarter worth about $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in Abbott Laboratories in the fourth quarter worth about $26,000. Finally, Abound Financial LLC purchased a new position in Abbott Laboratories in the fourth quarter worth about $26,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays raised its price target to $144 and keeps an “overweight” view, signaling confidence in Abbott’s outlook and providing a potential catalyst for buyers. Barclays raises price target on Abbott
• Positive Sentiment: Dividend-focused coverage highlights Abbott as a “Dividend King” on sale — analysts and income investors point to the company’s long dividend track record and yield as a reason to accumulate during recent weakness. A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
• Positive Sentiment: Independent analysis (Seeking Alpha) frames Abbott as a dividend aristocrat with attractive valuation and return potential for long-term, income-oriented investors — a supportive narrative for buy-and-hold holders. Abbott Laboratories: A Dividend Aristocrat With A Compelling Valuation And Return Potential
• Neutral Sentiment: Abbott released survey findings on chronic-disease prevention that bolster its public-health positioning and could help product demand over time, but this PR-driven item is unlikely to move near-term earnings materially. New survey finds most Americans believe chronic diseases are preventable
• Neutral Sentiment: Brokerage consensus remains mildly positive overall (reports note an average “Moderate Buy” rating), which may limit downside if fundamentals remain stable. Abbott Receives Average Rating of Moderate Buy
• Negative Sentiment: Analysts and preview pieces (Zacks/Yahoo) flag Abbott as unlikely to deliver an earnings beat next week — investors often sell into earnings when a beat looks improbable. Abbott Reports Next Week: Wall Street Expects Earnings Growth
• Negative Sentiment: Evercore cut its price target to $134 and other brokers (Goldman) trimmed targets (to $121) even while some maintained “buy” ratings — mixed/trimmed targets are weighing on sentiment. Evercore Cuts Abbott Price Target
• Negative Sentiment: Recent coverage notes share-price weakness (down ~7% month, ~20% over 3 months) and fading momentum; that trend can amplify declines as investors reprice risk. Assessing Abbott Valuation After Recent Share Price Weakness

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.